Down Syndrome Clinical Trials - Study of Alzheimer's Disease in Down Syndrome
Megadott ok: COVID delayed study timelines. Competing studies began enrolling at our sites.
Key facts
- Where
- Atlanta, Baltimore, Boston, Charlestown, Chicago, Cincinnati, Cleveland, Durham, Fairway, Irvine, La Jolla, Lexington, Park Ridge és Phoenix, Egyesült ÁllamokSee the 14 sites
Where in Egyesült Államok
- Emory UniversityAtlanta, Egyesült ÁllamokNo longer taking part
- Kennedy Krieger InstituteBaltimore, Egyesült ÁllamokNo longer taking part
- Massachusetts General HospitalBoston, Egyesült ÁllamokNo longer taking part
- Massachusetts General HospitalCharlestown, Egyesült ÁllamokNo longer taking part
- Rush University Medical CenterChicago, Egyesült ÁllamokNo longer taking part
- Cincinnati Children's Hospital Medical CenterCincinnati, Egyesült ÁllamokNo longer taking part
- Case Western Reserve UniversityCleveland, Egyesült ÁllamokNo longer taking part
- Duke University Medical CenterDurham, Egyesült ÁllamokNo longer taking part
- Kansas University Medical CenterFairway, Egyesült ÁllamokNo longer taking part
- University California IrvineIrvine, Egyesült ÁllamokNo longer taking part
- University of California San DiegoLa Jolla, Egyesült ÁllamokNo longer taking part
- University of KentuckyLexington, Egyesült ÁllamokNo longer taking part
- Advocate HealthPark Ridge, Egyesült ÁllamokNo longer taking part
- Barrow Neurological InstitutePhoenix, Egyesült ÁllamokNo longer taking part
Trial details
- Who runs it
- LuMind IDSC Foundation
- Trial code
- NCT04149197
- Record updated
- 2024. június 27.
- Original description
The primary objective is to characterize trajectories of change on the primary outcome measures in this study population through longitudinal collection of measures of cognition, function, behavior, and health status.Read full original descriptionShow less
The Down Syndrome Clinical Trials Network (DS-CTN) Study of Alzheimer's Disease in Down Syndrome
The primary objective is to characterize trajectories of change on the primary outcome measures in this study population through longitudinal collection of measures of cognition, function, behavior, and health status.
Inclusion: Age 25 years or older; Diagnosis of DS, typically supported by karyotype analysis documenting full trisomy for chromosome 21 or complete unbalanced translocation of chromosome 21. Karyotype analysis is not required for study entry; Participants, or Legal Authorized Representative, and their study partner if applicable, in the opinion of the investigator, are able to understand and willing to sign written informed consent; Participants must have a study partner who has frequent interaction with the participant on a regular basis, will agree to participate in annual clinic visits, can provide accurate responses to questions about the participant, and facilitate participation in the study visits, in the opinion of site PI or study coordinator; Participant and study partner must be capable of reliably completing study assessments.